ValiRx PLC
LSE:VAL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Suzhou Qingyue Optoelectronics Technology Co Ltd
SSE:688496
|
CN |
|
Shyft Group Inc
NASDAQ:SHYF
|
US |
|
Wellhope Foods Co Ltd
SSE:603609
|
CN |
|
Elite Material Co Ltd
TWSE:2383
|
TW |
|
V
|
Vow Green Metals AS
OSE:VGM
|
NO |
|
EXEO Group Inc
TSE:1951
|
JP |
|
U-Tech Media Corp
TWSE:3050
|
TW |
|
Swatch Group AG
SIX:UHR
|
CH |
ValiRx PLC
Research & Development
ValiRx PLC
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ValiRx PLC
LSE:VAL
|
Research & Development
-£229.2k
|
CAGR 3-Years
17%
|
CAGR 5-Years
24%
|
CAGR 10-Years
20%
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Research & Development
-$150.2m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-104%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Research & Development
-£274.9m
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Research & Development
-$119m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Research & Development
£9.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ValiRx PLC
Glance View
ValiRx Plc is a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary and novel technology for precision medicines towards commercialization and partnering. The company is headquartered in Nuneaton, Warwickshire and currently employs 10 full-time employees. The company went IPO on 2000-02-28. The firm is engaged in the development of oncology therapeutics and companion diagnostics. The company focuses on the development of treatments in cancer and women’s health. Its product pipeline includes VAL201, VAL301, VAL401 and BC201. Its VAL201 is an anti-cancer therapeutic drug, which is in clinical trials for the treatment of prostate cancer. Its VAL301 for the treatment of women with endometriosis. Its VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. Its BC201 is a combination of the peptide ingredient of VAL201 with active components to dampen this excessive immune response and consequently improve severe symptoms of Covid-19. The company operates through divisional companies, including ValiPharma and ValiSeek.
See Also
What is ValiRx PLC's Research & Development?
Research & Development
-229.2k
GBP
Based on the financial report for Jun 30, 2025, ValiRx PLC's Research & Development amounts to -229.2k GBP.
What is ValiRx PLC's Research & Development growth rate?
Research & Development CAGR 10Y
20%
Over the last year, the Research & Development growth was 23%. The average annual Research & Development growth rates for ValiRx PLC have been 17% over the past three years , 24% over the past five years , and 20% over the past ten years .
